EMA to revoke market approval for Novartis' sickle cell drug
Europe’s drug regulator is recommending that Novartis’s Adakveo, against sickle cell anemia, is removed from the market after an investigation questions its side effects.
by ulrich quistgaard, translated by daniel pedersen
The European Medicines Agency (EMA) seeks to revoke the marketing authorization for Adakveo, a sickle cell disease treatment marketed by Swiss pharmaceutical firm Novartis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CHMP recommends two drugs in May
For subscribers
